Healthcare security firm Imprivata has entered a strategic agreement with cybersecurity experts Symantec on a comprehensive fingerprint biometric solution for electronic prescribing of controlled substances.The companies have said that the collaboration will involve Symantec Norton Secure Login, acting as a FICAM-certified Credential Service Provider (CSP). Meanwhile, Symantec Validation and ID Protection Services (VIP) will integrate with Imprivata's Confirm ID.This means that the companies will be able to simplify the process of identity-proofing and credentialing prescribers to comply with DEA requirements for electronic prescribing of controlled substances.”Our strategic partnership with Symantec provides customers with a complete, DEA-compliant solution for identity-proofing individual prescribers to help meet regulatory requirements for EPCS. The integrated solution gives administrators a single workflow for enabling the use of Symantec one-time password (OTP) tokens and/or Imprivata's fingerprint biometric identification for EPCS,” said David Ting, chief technology officer at Imprivata. “This gives hospitals greater flexibility in matching the best two-factor authentication option to fit their prescribers' clinical workflow requirements.”The DEA mandates that individual prescribers obtain two-factor authentication credentials from a approved CSP.”We look forward to working with Imprivata to help customers solve the critical compliance and secure workflow challenges associated with EPCS,” said Dawn Swainston, director, Business Development for Healthcare, Government and Education, Symantec.”We view EPCS as a tremendous market opportunity as organizations look to comply with the rigid security requirements for e-Prescribing, enable secure processes for managing identities and data, and address drug diversion and abuse.”
Select Page















